Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

July 23, 2021

FDA approves Merck, Eisai’s Keytruda and Lenvima combination for endometrial cancer

Merck and Eisai have secured approval from the US Food and Drug Administration (FDA) for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination to treat patients with certain types of advanced endometrial carcinoma.

FDA approves Merck, Eisai’s Keytruda and Lenvima combination for endometrial cancer